Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

RE Royal, C Levy, K Turner, A Mathur… - Journal of …, 2010 - journals.lww.com
New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can
mediate an immunologic tumor regression in other histologies. This phase II trial evaluated
the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally
advanced or metastatic pancreas adenocarcinoma with measurable disease, good
performance status, and minimal comorbidities. Ipilimumab was administered intravenously
(3.0 mg/kg every 3 wk; 4 doses/course) for a maximum of 2 courses. Response rate by …